From: SULFs in human neoplasia: implication as progression and prognosis factors
HM cohort (OS) | |||
---|---|---|---|
Pronostic variable | Proportional hazard ratio | P-value | |
Univariate Cox analysis | SULF2 ISS | 4.08 1.73 | 0.007 0.001 |
Multivariate Cox analysis | SULF2 ISS | 3.65 1.70 | 0.028 0.001 |
Univariate Cox analysis | SULF2 b2M Alb | 4.08 1.10 1.60 | 0.007 0.0001 0.04 |
Multivariate Cox analysis | SULF2 b2M Alb | 3.49 1.10 1.35 | 0.03 0.0001 0.24 |
Univariate Cox analysis | SULF2 HRS | 4.08 2.30 | 0.007 0.002 |
Multivariate Cox analysis | SULF2 HRS | 4.11 2.31 | 0.01 0.002 |
Univariate Cox analysis | SULF2 MS group | 4.08 2.14 | 0.007 0.001 |
Multivariate Cox analysis | SULF2 MS group | 3.84 1.97 | 0.023 0.028 |
Univariate Cox analysis | SULF2 IFM score | 4.08 3.09 | 0.007 0.0001 |
Multivariate Cox analysis | SULF2 IFM score | 4.29 3.22 | 0.014 0.0001 |
Univariate Cox analysis | SULF2 GPI | 4.08 2.21 | 0.007 0.0001 |
Multivariate Cox analysis | SULF2 GPI | 4.47 2.25 | 0.011 0.0001 |
Univariate Cox analysis | SULF2 MYEOV | 4.08 3.16 | 0.007 0.05 |
Multivariate Cox analysis | SULF2 MYEOV | 3.71 2.76 | 0.026 0.08 |
Univariate Cox analysis | SULF2 CD200 | 4.08 2.05 | 0.007 0.03 |
Multivariate Cox analysis | SULF2 CD200 | 3.86 1.03 | 0.02 0.05 |